P46409 9th Annual Cell Line Development and Engineering Asia
Download Brochure Request

Register your interest

Comments

Register your interest

Comments

9th Annual Cell Line Development and Engineering Asia

18 – 20 May 2020, Shanghai, China

Book Now

LOCAL CHINA COMPANIES RATES AVAILABLE. 中国企业可享有独家优惠价!
SPECIAL GROUP RATES FOR 2 OR MORE. 2名及以上代表注册立享团队优惠价。SEE PRICING BELOW.

overview

The global market size for cell line development is expected to exceed USD 7.5 billion by 2024. Some key market drivers include the demand for cell therapies, growing oncology market, increasing demand for vaccines and monoclonal antibodies, and continued growth in the vaccine market.

Aimed at providing a commercial snapshot of new market opportunities, yet retaining its focus on scientific and technical best practice use cases, the 8th Annual Cell Line Development & Engineering Asia summit will continue to provide unique learning and sharing opportunities for the industry.

Discussion themes

  • Impact of the surging biologics and cell therapy market on cell line development
  • Cell line market trends by source – mammalian and non-mammalian, and influencing factors
  • Market outlook for cell lines across drug discovery, bioproduction, toxicity testing, and tissue engineering
  • CAR-T cell development and manufacturing
  • Growth prospects in the primary cell line and tissue engineering
  • Use cases of 3D cell culture in primary cell lines
  • The growing use of reagents and media, and technical best practice
  • In-source or out-source cell line development
  • Best practice to ensure clonality in new cell lines and legacy cell lines
  • Procs and cons of generation sequencing (NGS) for proving the clonality of legacy production cell lines
  • The use of synthetic biology to help understand success and failure in cell line development
  • CRIPSR in cell line development
  • Comparingculture methods – batch, fedbatch, and perfusion processes
  • Tailoring cell line development programs for your project

For more information, visit www.biopharmaproduction.com >>

agenda

8:00 am

Registration Starts & Morning Coffee

9:00 am

Chairperson’s Opening Remarks

Judith Li, Partner, Lilly Asia Ventures, Hong Kong

OPENING KEYNOTE SESSIONS JOINT PLENARY SESSIONS WITH 9TH ANNUAL BIOMANUFACTURING, 10TH ANNUAL BIOSIMILARS ASIA, 4TH ANNUAL CLINICAL TRIALS, CELL & GENE THERAPY CONFERENCES

9:05 am

Investor Talk by Lilly Asia Ventures: China’s Great Leap Forward in Biotech

Judith Li, Partner, Lilly Asia Ventures, Hong Kong

9:30 am

  • Recent regulatory developments – obstacle or opportunity?
  • The clinical trials market
  • China market scenarios on CAR-T & CRISPR technology
  • Growth prospects on cell line development market and therapeutics
  • Current state of affairs on biosimilars
  • Digitalisation of biopharma value chain – is China ahead of the game?
  • How are new business models creating opportunities?

10:30 am

Morning Networking & Refreshment Break

8TH ANNUAL CELL LINE DEVELOPMENT & ENGINEERING ASIA COMMENCES

11:20 am

Chairperson’s Opening Remarks

Thomas Kelly, Scientist, Cell & Developability Sciences, Pharmaceutical Development & Manufacturing Sciences (PDMS), Janssen R&D, U.S.

ASSURANCE AND PROOF OF MONOCLONALITY

11:30 am

  • Pros and cons of using transposase-mediated integration over site-directed or random integration of plasmid DNA
  • Higher titers for stable transfection pools, and higher titers with improved stability for clones by using transposase
  • Assurance of monoclonality in one seeding and imaging step by use of the Verified In-Situ Plate Seeding (VIPS) system

12:00 pm

  • Intelligent transposase mediated integration to deliver highly uniform cell pools up to 5+g/L and clones up to 7+g/L
  • High efficiency seeding and imaging to rapidly deliver desired clones in a reduced number of microplates
  • Assurance of a high level of monoclonality

12:30 pm

Networking Lunch

NEW TECHNOLOGIES AND HOST CELL LINES

1:30 pm

  • The critical role of N-Glycans in the pharmacology of biotherapeutics
  • Next generation sample preparation workflows and advanced analytical tools shorten the time to results from days to hours

2:50 pm

  • Transforming and accelerating complex manufacturing processes for bio-therapeutic drugs through novel methods
  • Optimising the drug manufacturing process through the fully-automatable Quantum fluorescence polarisation technology platform and novel ChemStress technology
  • Providing early, key insights to promote the chance of identifying high producing, stable cell clones in a reduced time-frame

3:30 pm

Afternoon Networking & Refreshment Break

4:00 pm

Characterization of Single Cell, Monoclonal Populations Using the Beacon Platform

Dr. Ben Borgo, Associate Director, Assays, Reagents, and Software, Berkeley Lights, U.S.

ADVANCES IN GENOME EDITING TECHNOLOGIES – CRISPR & CAR-T

4:40 pm

  • Selecting the cell source
  • Optimising differentiation conditions with small molecules
  • Choosing bioprocess / bioreactors for cell intensification

5:10 pm

Chairperson’s Summary and End of Conference Day 1

8:30 am

Morning Coffee

9:00 am

Chairperson’s Opening Remarks

Dr. Dong-Yup Lee, Associate Professor, College of Engineering, Sung Kyun Kwan University (SKKU), South Korea

HIGH THROUGHPUT PLATFORMS FOR CELL LINE DEVELOPMENT

9:05 am

  • Presented emerging trends and technologies for CHO cell line development and engineering
  • Discussed mammalian systems biotechnology for targeted and precise CHO cell line development and engineering
  • Integrated multi-omics profiles with a genome-scale metabolic model of CHO cells

9:35 am

  • The case for automated high-throughput solutions over manual screening methods in the production of monoclonal cell lines
  • Outline of possible high-resolution, image-based process qualifications for each individual step in CLD using high-throughput imaging systems developed by SYNENTEC®
  • Pathways and demonstrated methods of generating supportive data for regulatory approval of clonal cell lines for biopharmaceutical production

10:05 am

  • Gentle and efficient single-cell dispensing with assurance of clonality ensures highest cell viability and best possible colony growth
  • Due to disposables cross-contamination is prevented while single cells are sorted due to brightfield and fluorescence into 96- and 384-well plates within a few minutes
  • Most of the worlds top10 pharma companies – which are perfectly aware of the omnipresent regulatory requirements – apply easy-to-use cytena instruments in their cell line development

10:35 am

Morning Networking & Refreshment Break

11:05 am

Chairperson’s Opening Remarks

Dr. Qinghai Zhao, Vice President, Technical Development and Manufacturing, Forty-Seven Inc. USA

11:10 am

  • Cell line development outsourcing and insourcing
  • Balance between quality, timeline and cost
  • Use cases and lessons learnt

11:40 am

  • Application of targeted integration technology
  • Use stable pool for candidate selection
  • Case study of CLD with speed to IND

12:20 pm

Networking Lunch

2:10 pm

  • Cell line development as a manufacturing process
  • Productivity of cell line and manufacturing cost
  • Glycosylation monitoring

2:50 pm

Combined Q&A Session

Dr. Jerry Yang, Senior Vice President, Process & Product Development, Hangzhou JUST Biotherapeutics, China

Dr. Qinghai Zhao, Vice President, Technical Development and Manufacturing, Forty-Seven Inc. USA

Dr. Cuiyun Xu, Director, Upstream Process Development, Shanghai Henlius Biotech, Inc., China

Eric Chang, Head of Cell Line Development, JHL Biotech, Taiwan

3:30 pm

Afternoon Networking & Refreshment Break

CLOSING PLENARY PANEL JOINT PLENARY SESSIONS WITH 9TH ANNUAL BIOMANUFACTURING, 10TH ANNUAL BIOSIMILARS ASIA, 4TH ANNUAL CLINICAL TRIALS, CELL & GENE THERAPY CONFERENCES

5:00 pm

Chairperson’s Summary and End of Conference

9:00 am

China’s biopharma industry continues to grow rapidly  and hails as a major investment region in the world. With tides of tech innovation, market growth in CRO, CMO and CDMO, a numerous clinical trials projects lined-up, newly discovered therapies to the market and upgrading manufacturing facilities to name a few. This workshop aims to provide a strategic snapshot of the investment landscape for biopharma medicine, and covers practical aspects on how biotech companies can navigate the investment and pricing options for related drugs and treatments to generate better returns.

You will learn:

  • Financing clinical trials operations
  • R&D investment and financing models
  • Manufacturing financing
  • Financial partnership with Chinese pharma and biotech
  • Biosimilars products financing
  • Going Public and Listing insights
  • Deal, debt and equity structuring

1:00 pm

End of Workshop

pricing

Packages Price
2 Day Conference - International Companies, Global HQ Located Outside ChinaUS $1895US $1695Early BirdEarly Bird
2 Day Conference - Local China CompaniesUS $977US $827Early BirdEarly Bird
Group Rate of 2 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1495Early Bird
Group of 2 or more delegates - Local China CompaniesUS $752Early Bird
Group Rate of 4 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1295Early Bird
Group of 4 or more delegates - Local China CompaniesUS $676Early Bird
Extras Price
Pre Conference Workshop - International Companies, Global HQ Located Outside China US $300
Pre Conference Workshop - Local China Companies US $150
Gala Dinner US $50

Early Bird Rate: Register & Pay by 27 March 2020

  • Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)

CNY Pricing

  • 2 Day Conference: CNY 6,500
  • Group of 2 or more delegates: CNY 5,000
  • Group of 4 or more delegates: CNY 4,500
  • Pre Conference Workshop: CNY 1,000
  • Gala Dinner: CNY 350

Sponsorship

Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.

speakers

Judith Li

Partner, Lilly Asia Ventures, Hong Kong

Feng Tao

Founding Partner, Biotrack Capital, China

He Ting

Chief Executive Officer, ImmunoChina, China

Dong Wei

CEO, Edigene, China

Peter Luo

CEO, Adagene Pharma, China

Jonathan Zhao 4th Annual Bioprocess and Technology 2018

Jonathan Zhao

Co-Founder and Executive Chairman, TRANSCENTA HOLDING, China

Thomas Kelly

Scientist, Cell & Developability Sciences, Pharmaceutical Development & Manufacturing Sciences (PDMS), Janssen R&D, U.S.

George Hutchinson

Head of Global Distribution, Solentim, UK

Dr. John Yan

Applications Scientist, ProZyme, U.S.

Dr. Senyon Choe (Teddy)

Professor, Biology, University of California San Diego (UCSD), U.S. and President and Director of Joint Center for Biosciences, South Korea

Dr. Carolanne Doherty

Marketing & Sales Manager, Valitacell, Ireland

Dr. Ben Borgo

Associate Director, Assays, Reagents, and Software, Berkeley Lights, U.S.

Dr. Steve Oh

Institute Scientist and Director, Stem Cell Bioprocessing, Bioprocessing Technology Institute, A*STAR, Singapore

Dr. Dong-Yup Lee

Associate Professor, College of Engineering, Sung Kyun Kwan University (SKKU), South Korea

Ben Werdelmann

Director, Business Development and Applications, SYNENTEC GmbH, Germany

Dr. Fabian Stumpf

CMO, Cytena, Germany

Dr. Qinghai Zhao

Vice President, Technical Development and Manufacturing, Forty-Seven Inc. USA

Dr. Jerry Yang

Senior Vice President, Process & Product Development, Hangzhou JUST Biotherapeutics, China

Dr. Cuiyun Xu

Director, Upstream Process Development, Shanghai Henlius Biotech, Inc., China

Eric Chang

Head of Cell Line Development, JHL Biotech, Taiwan

Dr Jerry Dong

Vice President of CMC and Regulatory Affairs, Shanghai Henlius Biotech, Inc.

Chen-Yuan Lin

Ward Director and Attending Physician at the Division of Hematology and Oncology, China Medical University Hospital, Taiwan

Dr Lin Shiwen

Vice President of Downstream Process Development, WuXi Biologics, China

Xiaodi Su

Senior Investment Manager, Lilly Asia Ventures, China

Jieyu Zou

Vice President, Lilly Asia Ventures, China

when & where

18 - 20 May 2020

contact

Still have a question?

sponsors

exhibitors

Partners

Conference Partner Conference Partner

STAY UPDATED ON OUR NEWS & EVENTS

IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more

We are changing our brand to Informa Connect
Learn More
close-image